Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
El Gaucho schreef op 8 april 2015 18:48 :
Zie net dat de CEO bijna 50.000 aandelen heeft verkocht afgelopen maandag... Hoe onprofessioneel! Daar gaat toch een enorme signaalwerking van uit!
We are surprised and very disappointed that MYDICAR failed to meet the endpoints in the CUPID2 trial.........said Krisztina Zsebo, Ph.D., CEO of Celladon. Met de nadruk op Surprised....ammehoela.
idd....de koersontwikkeling vanaf het moment dat de daling inzette geeft echt te denken! (dus ook nog vóór de CEO verkocht) Nog geen 2 maanden geleden boven de 27$ en dan naar 13,68$ 'zonder' nieuws???
Celladon spoils the gene therapy party Date April 27, 2015 Did somebody say gene therapy was undergoing a resurgence? Celladonyesterday brought the party back down to earth with the revelation that a phase II heart failure trial had shown its Mydicar project to be an unmitigated failure. Some credit should be given to management for spelling out in no uncertain terms that Mydicarhad flunked both the primary and secondary endpoints of the Cupid2 study, though analysts who had hyped the highly risky trial today looked less impressive. Attention now turns to other companies that had basked in the reflected glow of Bluebird Bio, whose success had started the gene therapy rally. The excitement around Bluebird concerned a tiny study presented at December’s ASH conference. Though this had detailed just four patients, out of eight treated so far, it suggested that Bluebird’s LentiGlobin could revolutionise treatment of beta-thalassaemia; the US biotech’s stock has nearly tripled since then. Then there is UniQure’s Glybera, whose 2013 EU approval for lipoprotein lipase deficiency was the world’s first ever for a gene therapy. While Glybera seems doomed economically, UniQurethis month struck a major alliance with Bristol-Myers Squibb over separate assets. Earlier this year Sanofi endorsed Voyager Therapeutics with a $100m deal, while Spark Therapeutics’ Nasdaq IPO was enthusiastically received. No silver lining For Celladon, however, it is hard to see a silver lining after the failure of Mydicar in Cupid2, which had enrolled 250 patients with ischaemic or dilated cardiomyopathy and compared the gene therapy against placebo. Even on a modified intent-to-treat basis the primary endpoint – improvement in heart failure-related hospitalisations or ambulatory treatment for worsening heart failure – was a fail: risk of progression was reduced by 7% on average, but the upper bound of the confidence interval was 1.65 and the p value was a highly non-significant 0.81. The secondary endpoint, all-case death, also failed to show a benefit for Mydicar. On a call Celladon said it would implement staff layoffs and investigate all options for the company; the group ended 2014 with $85m in cash, which it says is enough for at least a year excluding the impact of cost cutting. The company also said it would investigate whether the problem with Cupid2 was lack of efficacy or inadequate delivery of Mydicar into cardiomyocytes. The agent uses a viral vector to deliver a gene encoding production of the enzyme SERCA2a to cardiac tissue to improve contraction in heart muscle cells. Targeted Mydicar was a legacy project of Targeted Genetics, a group that now exists as the bacteriophage-focused business Ampliphi Biosciences; by virtue of this Ampliphi had been due a 10% royalty on Mydicar sales. Keen biotech watchers might have spotted another link: Targeted Genetics was also the originator of UniQure’s Glybera. While Glybera did secure EU approval, under exceptional circumstances, it is still not launched, the first commercial patient not expected to be treated until mid-2015. And its continuing review recently hit another snag. At least UniQure bulls can point to the group’s deal with Bristol-Myers Squibb, which concerned the heart failure candidate AAV-S100A1 and three other targets, none of which is related to Glybera (UniQure deal confirms red-hot interest in advanced therapies, April 7, 2015). What does all this mean for gene therapy in general? Mydicar is clearly a setback for the field, though if Bristol had been looking specifically at cardiovascular projects it can at least say it backed the right horse. UniQure opened up 1% this morning, while Bluebird was off 1%. Celladon, meanwhile, was crushed, plummeting 78%. In a note in January Stiefel Niclaus analysts had spelled out their expectation of a positive Cupid2 readout, and called Mydicar a “massive commercial opportunity [which] is a single hurdle away”. But after peaking in March the stock went into freefall, with sellers including the company’s chief executive, Krisztina Zsebo. In hindsight that provided a pretty large red flag as to the direction in which Mydicar was heading.www.evaluategroup.com/Universal/View.... Btw: Glybera approved in 2012. (Reeds doorgegeven). AAV1->University of Pennsylvania/Genovo/Targeted Genetics/ $CLDN/AMT www.genengnews.com/gen-articles/glybe...
flosz schreef op 27 april 2015 16:39 :
[...]
We are surprised and very disappointed that MYDICAR failed to meet the endpoints in the CUPID2 trial.........said Krisztina Zsebo, Ph.D., CEO of Celladon.
Met de nadruk op Surprised....ammehoela.
Doet me denken aan kapitein Francesco Schettino van de Costa Concordia...
Een ding is voor mij superbelangrijk in al dit tumult: gentherapie kan je niet meer wegzetten als dagdromerij. De patienten in studies in de NEJM met Hemofilie B zijn echte patienten die echt hun Eigen factor 9 maken dankzij gentherapie. Ook bij Glybera staat op zijn minst de veiligheid niet ter discussie. Dit gaat niet meer weg. Het wordt alleen maar groter. En soms mislukt er iets. Zoals nu.
Het staat nu OS. Is dit aandeel voor deze prijs een gokje waard? Zit er voldoende kennis in? Overname kandidaat? Hebben ze voldoende cash om verbeteringen aan te brengen?
rationeel schreef op 27 april 2015 21:25 :
Het staat nu OS. Is dit aandeel voor deze prijs een gokje waard? Zit er voldoende kennis in? Overname kandidaat? Hebben ze voldoende cash om verbeteringen aan te brengen?
Kijk nog eens terug op Sarepta Therapeutics...
Meer dan 30 miljoen omzet. En tegenover iedere verkoper stand een koper;)
rationeel schreef op 27 april 2015 23:35 :
Meer dan 30 miljoen omzet. En tegenover iedere verkoper stand een koper;)
Ja, en wellicht dezelfde koper... het management, dat de stukken voor een prikkie terug kocht. ;-) Het blijft een vallend mes.
Sarepta: Van 12,12 naar 40, en terug naar 11,33. Smullen voor een getallen fetisjist:), of zie het als humor;)
Heart failure gene therapy disappoints but experts keep the faithwww.nature.com/nbt/journal/v33/n6/ful... Via: twitter.com/festivus159 $QURE $CLDN Heart failure gene therapy disappoints but experts keep the faith.t.co/TGzhXU9vO7 Comparison of $QURE & $CLDN programs
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
887,44
+0,99%
EUR/USD
1,0762
+0,34%
FTSE 100
8.213,49
+0,51%
Germany40^
18.017,10
+0,09%
Gold spot
2.301,75
0,00%
NY-Nasdaq Composite
16.156,33
+1,99%
Stijgers
Dalers